Bayer statement on jury’s decision in phase one of California glyphosate trial

Bayer Animal Health launches Seresto™ collar in China

The flea and tick collar Seresto™ is one of the fastest growing brands in the Animal Health industry. ...

Phase III clinical trial with Bayer’s nifurtimox demonstrates safety and efficacy of new formulation to treat children with Chagas disease

Largest clinical treatment study to date in pediatric patients with Chagas disease / Easily dividable and dispersible nifurtimox tablet for improved weight-adjusted dosing of newborns, infants, and children ...

Bayer submits European marketing authorization application for darolutamide

Third submission for darolutamide in two weeks underscores Bayer´s commitment to fill an unmet need for men with nmCRPC worldwide ...

Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition

Innovative concepts with sustainable and systematic change potential honored by Bayer Foundation / Awards for five international initiatives that can help improve many millions of lives / Around EUR 650,000 presented to 39 initiatives offering new solutions to improve living conditions since 2010 ...

Bayer presents global dairy cattle health experts at 2nd Dairy Summit

Thought leaders address five core pillars to advancing dairy cattle health ...

Bayer submits darolutamide for marketing authorization in Japan

Regulatory submission based on positive data from Phase III ARAMIS study ...

Conviso™ Smart: Successful licensing agreement between Bayer AG, KWS SAAT SE and MariboHilleshög

Bayer presents next generation CT injector, MEDRAD™ Centargo, at European Congress of Radiology 2019

New CT injection system provides range of innovative features which simplify workflow to help ease increasing workload of radiology departments ...

Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin

Scientist at the Institute for Cardiovascular Prevention at the Ludwig-Maximilians-University in Munich is honored for his outstanding research in the area of immunity of atherosclerosis-brain interfaces ...